# GLYCOPROTEINS IN NORMAL & LEUKEMIC CELL DIFFERENTIATION

> **NIH NIH R01** · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · 1989 · $215,987

## Abstract

The primary objective is to study the differentiation of membranes in human
leukocytes (myeloid and lymphoid cells) and to evaluate cell surface
carbohydrates and glycoproteins as onco-differentiation markers that may be
shared by both leukemic cells and normal cells, depending on the stage of
differentiation.  Two major aspects deal with:

(1) Elucidation of the structure of leukosialin, a major cell surface
sialoglycoprotein expressed on various leukocytes.  We have isolated a
major cell surface sialoglycoprotein from myeloid cells and found that this
glycoprotein is expressed in various leukocytes including
granulocyte/monocyte, B-lymphoid and T-lymphoid cell lineages.  In
addition, we have discovered that this glycoprotein is heavily glycosylated
by 0-linked oligosaccharides and the structures of those 0-linked
oligosaccharides are characteristic to each cell lineage and to different
maturation stages of myeloid cells.  Further studies will characterize
carbohydrate chains of leukosialin, along the differentiation pathways in
various cell lineages, aiming at elucidating possible roles of leukosialin
glycosylation.  These studies will be complemented by isolation and
characterization of cDNA coding for Leukosialin, which will enable us to
elucidate its peptide sequence.

(2) Analysis of the carbohydrate chains of cell surface glycoproteins and
glycolipids in leukemic cells.  We found that polylactosaminoglycans and
glycolipids of chronic myelogenous leukemia (CML) cells express unique
carbohydrate structures, such as
NeuNAcAlpha2to3GalBeta1to4(FucAlpha1to3)GlcNAcBeta1to3GalBeta1to4(FucAlpha1t
o3)-GlcNActo, and
NeuNAcAlpha2to3GalBeta1to4GlcNAcBeta1toGalBeta1to4(FucAlpha1to3)GlcNActo.
These structures are apparently absent in normal mature granulocytes or
acute myelogenous leukemia cells.  Further studies will be to generate
monoclonal antibodies specific to these carbohydrates and determine if
these carbohydrates can be used as CML markers.  The structural analysis on
carbohydrates present in other leukemic cells, particularly B-,lymphocytic
leukemia will be initiated with the aim of identifying carbohydrate
structures unique to these leukemic cells.

## Key facts

- **NIH application ID:** 3171645
- **Project number:** 5R01CA033895-07
- **Recipient organization:** SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- **SAM.gov UEI:** PHMKYKKJLQS1
- **Principal Investigator:** MINORU FUKUDA
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $215,987
- **Award type:** 5
- **Project period:** 1983-01-01 → 1991-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171645

## Citation

> US National Institutes of Health, RePORTER application 3171645, GLYCOPROTEINS IN NORMAL & LEUKEMIC CELL DIFFERENTIATION (5R01CA033895-07). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171645. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*